These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38053515)

  • 1. Health-related quality of life in pre-pubertal children with pediatric growth hormone deficiency: 12-month results from a phase 3 clinical trial of once-weekly somatrogon versus once-daily somatropin.
    Loftus J; Quitmann J; Valluri SR
    Curr Med Res Opin; 2024 Feb; 40(2):175-184. PubMed ID: 38053515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study.
    Deal CL; Steelman J; Vlachopapadopoulou E; Stawerska R; Silverman LA; Phillip M; Kim HS; Ko C; Malievskiy O; Cara JF; Roland CL; Taylor CT; Valluri SR; Wajnrajch MP; Pastrak A; Miller BS
    J Clin Endocrinol Metab; 2022 Jun; 107(7):e2717-e2728. PubMed ID: 35405011
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Gomez R; Khadilkar V; Shembalkar J; Chu DM; Ko CW; Wajnrajch MP; Wang R
    J Pediatr Endocrinol Metab; 2024 Jun; 37(6):525-531. PubMed ID: 38717038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physician experience with once-weekly somatrogon versus once-daily rhGH regimen in pediatric patients with growth hormone deficiency: a cross-sectional survey of physicians from the global phase 3 study.
    Gomez R; Lamoureux R; Turner-Bowker DM; Loftus J; Maghnie M; Miller BS; Polak M; Yaworsky A
    Front Endocrinol (Lausanne); 2023; 14():1254424. PubMed ID: 37955005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin®) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study.
    Horikawa R; Tanaka T; Hasegawa Y; Yorifuji T; Ng D; Rosenfeld RG; Hoshino Y; Okayama A; Shima D; Gomez R; Pastrak A; Castellanos O
    Horm Res Paediatr; 2022; 95(3):275-285. PubMed ID: 35417909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment.
    Zadik Z; Zelinska N; Iotova V; Skorodok Y; Malievsky O; Mauras N; Valluri SR; Pastrak A; Rosenfeld R
    J Pediatr Endocrinol Metab; 2023 Mar; 36(3):261-269. PubMed ID: 36732285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Burden of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Randomized Study.
    Maniatis AK; Carakushansky M; Galcheva S; Prakasam G; Fox LA; Dankovcikova A; Loftus J; Palladino AA; de Los Angeles Resa M; Turich Taylor C; Dattani MT; Lebl J
    J Endocr Soc; 2022 Oct; 6(10):bvac117. PubMed ID: 36101713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychometric properties of the quality of life in short statured youth (QoLISSY) questionnaire within the course of growth hormone treatment.
    Bloemeke J; Silva N; Bullinger M; Witt S; Dörr HG; Quitmann J
    Health Qual Life Outcomes; 2019 Mar; 17(1):49. PubMed ID: 30885197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness and cost-utility analysis of somatrogon once-weekly injections vs. daily growth hormone injection for treating paediatric growth hormone deficiency in Ireland.
    Rivolo S; Loftus J; Peter B; Fahey M; Kongnakorn T
    J Med Econ; 2023; 26(1):963-972. PubMed ID: 37527156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Somapacitan Relative to Somatrogon and Lonapegsomatropin in Pediatric Growth Hormone Deficiency: Systematic Literature Review and Network Meta-analysis.
    de Fries Jensen L; Antavalis V; Odgaard-Jensen J; Rossi A; Pietropoli A; Højby M
    Adv Ther; 2024 Nov; 41(11):4098-4124. PubMed ID: 39261416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Explaining parent-child (dis)agreement in generic and short stature-specific health-related quality of life reports: do family and social relationships matter?
    Quitmann J; Rohenkohl A; Sommer R; Bullinger M; Silva N
    Health Qual Life Outcomes; 2016 Oct; 14(1):150. PubMed ID: 27769269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The psychometric evaluation of the quality of life in short stature youth (QoLISSY) instrument for German children born small for gestational age.
    Sommer R; Blömeke J; Bullinger M; Quitmann J
    J Endocrinol Invest; 2018 Oct; 41(10):1185-1191. PubMed ID: 29455392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parental perception of health-related quality of life in children and adolescents with short stature: literature review and introduction of the parent-reported QoLISSY instrument.
    Quitmann J; Rohenkohl A; Bullinger M; Chaplin JE; Herdman M; Sanz D; Mimoun E; Feigerlova E; DeBusk K; Power M; Wollmann H; Pleil A
    Pediatr Endocrinol Rev; 2013 Dec; 11(2):147-60. PubMed ID: 24575550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the American-English Quality of Life in Short Stature Youth (QoLISSY) questionnaire in the United States.
    Bullinger M; Sommer R; Pleil A; Mauras N; Ross J; Newfield R; Silverman L; Rohenkohl A; Fox J; Quitmann J
    Health Qual Life Outcomes; 2015 Apr; 13():43. PubMed ID: 25889818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.
    Thornton PS; Maniatis AK; Aghajanova E; Chertok E; Vlachopapadopoulou E; Lin Z; Song W; Christoffersen ED; Breinholt VM; Kovalenko T; Giorgadze E; Korpal-Szczyrska M; Hofman PL; Karpf DB; Shu AD; Beckert M
    J Clin Endocrinol Metab; 2021 Oct; 106(11):3184-3195. PubMed ID: 34272849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial.
    Maniatis AK; Nadgir U; Saenger P; Reifschneider KL; Abuzzahab J; Deeb L; Fox LA; Woods KA; Song W; Mao M; Chessler SD; Komirenko AS; Shu AD; Casella SJ; Thornton PS
    Horm Res Paediatr; 2022; 95(3):233-243. PubMed ID: 35263755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the Flemish version of the Quality of Life in Short Stature Youth (QoLISSY) questionnaire.
    Rohenkohl AC; De Schepper J; Vanderfaeillie J; Fricke K; Hendrickx S; Lagrou K; Bullinger M; Quitmann J;
    Acta Clin Belg; 2014 Jun; 69(3):177-82. PubMed ID: 24694268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone treatment in children with short stature: impact of the diagnosis on parents.
    Witt S; Bloemeke J; Bullinger M; Dörr HG; Silva N; Quitmann JH
    J Pediatr Endocrinol Metab; 2024 Apr; 37(4):326-335. PubMed ID: 38421314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric performance of the Quality of Life in Short Stature Youth (QoLISSY) questionnaire in a randomized open-label comparator trial in idiopathic short stature.
    Bloemeke J; Balacano Valdez R; Mauras N; Mericq V; Ross J; Permuy J; Quitmann J; Bullinger M
    J Pediatr Endocrinol Metab; 2019 Oct; 32(10):1089-1101. PubMed ID: 31557127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the Italian Quality of Life in Short Stature Youth (QoLISSY) questionnaire.
    Quitmann J; Giammarco A; Maghnie M; Napoli F; Di Giovanni I; Carducci C; Mohn A; Bullinger M; Sommer R
    J Endocrinol Invest; 2017 Oct; 40(10):1077-1084. PubMed ID: 28397185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.